| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1038: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over |
|
Medicine details |
|
| Medicine name | selpercatinib (Retsevmo®) |
| Formulation | 40 mg, 80 mg hard capsule |
| Reference number | 4400 |
| Indication | Monotherapy for the systemic treatment of advanced RET fusion-positive thyroid cancer in adults who require systemic therapy following prior treatment with sorafenib and/or lenvatinib. Monotherapy for the systemic treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents aged 12 years and older who require systemic therapy following prior treatment with cabozantinib and/or vandetanib |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/01/2021 |
| NICE guidance | |